Lyon 2020 HFA-ICOS baseline CV risk before VEGF inhibitors or VEGF TKIs
Lyon 2020 HFA-ICOS baseline CV risk before VEGF inhibitors or VEGF TKIs. Very high if heart failure/cardiomyopathy or arterial vascular disease. High if venous thrombosis, LVEF <50%, QTc >=480 ms, age >=75, hypertension, prior anthracycline, or >=5 medium poi…
by api.magentlab.com · discovered, not yet claimed by its owner · updated 2026-10-12
Mirrored from Coinbase's public x402 Bazaar. The description is the provider's own text and has not been reviewed here; the payment requirements are copied as published.
What it does
Lyon 2020 HFA-ICOS baseline CV risk before VEGF inhibitors or VEGF TKIs. Very high if heart failure/cardiomyopathy or arterial vascular disease. High if venous thrombosis, LVEF <50%, QTc >=480 ms, age >=75, hypertension, prior anthracycline, or >=5 medium points. Medium if 2-4 medium points. Guide <2% / 2-9% / 10-19% / >=20%. Not a device or treatment order.
Tags: hfa-icos · vegf-inhibitor · cardio-oncology · lyon-2020 · calculator · bazaar
Call contract
- Method
- POST
- Input
- HTTP request
- Output
- json
- Last paid call
- 2026-10-12
{
"items": [
{
"age_years": 50,
"arrhythmia": false,
"arterial_vascular_disease": false,
"ckd": false,
"current_or_significant_smoker": false,
"diabetes": false,
"elevated_bnp": false,
"elevated_troponin": false,
"heart_failure_or_cardiomyopathy": false,
"hyperlipidemia": false,
"hypertension": false,
"lvef_percent": 60,
"obesity": false,
"prior_anthracycline": false,
"prior_left_chest_or_mediastinal_rt": false,
"proteinuria": false,
"qtc_ms": 400,
"sex": "female",
"venous_thrombosis": false
},
{
"age_years": 50,
"arrhythmia": false,
"arterial_vascular_disease": false,
"ckd": false,
"current_or_significant_smoker": false,
"diabetes": false,
"elevated_bnp": false,
"elevated_troponin": false,
"heart_failure_or_cardiomyopathy": false,
"hyperlipidemia": false,
"hypertension": false,
"lvef_percent": 60,
"obesity": false,
"prior_anthracycline": false,
"prior_left_chest_or_mediastinal_rt": false,
"proteinuria": false,
"qtc_ms": 400,
"sex": "female",
"venous_thrombosis": false
}
]
}{
"count": 2,
"items": [
{
"age_years": 50,
"cardiotoxicity_guide": "<2%",
"citation": {
"authors": "Lyon AR, Dent S, Stanway S, et al.",
"doi": "10.1002/ejhf.1920",
"id": "lyon-2020",
"pmid": "32458582",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
},
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false,
"tier": "very_high"
},
{
"factor": "arterial_vascular_disease",
"points": 0,
"present": false,
"tier": "very_high"
},
{
"factor": "venous_thrombosis",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "lvef_lt_50",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "qtc_ge_480",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "age_ge_75",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "hypertension",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "prior_anthracycline",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "lvef_50_to_54",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "borderline_qtc",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "arrhythmia",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "age_65_to_74",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "diabetes",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "hyperlipidemia",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "ckd",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "proteinuria",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "obesity",
"points": 0,
"present": false,
"tier": "medium_1"
}
],
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"formula": "hfa_icos_vegf",
"formula_expression": "HFA-ICOS VEGF-inhibitor class (Lyon 2020): very_high if any very-high factor; else high if any high factor or medium_points>=5; else medium if medium_points 2-4; else low. medium_points = Medium 2 + Medium 1 only. Very high: heart_failure_or_cardiomyopathy, arterial_vascular_disease (IHD, PCI, CABG, stable angina, TIA, stroke, or PVD). High: venous_thrombosis, lvef_percent<50, qtc_ms>=480, age_years>=75, hypertension, prior_anthracycline. Medium 2: lvef 50-54, male 450<=qtc<480, female 460<=qtc<480, arrhythmia (AF/flutter/VT/VF). Medium 1: elevated_troponin, elevated_bnp, age 65-74, diabetes, hyperlipidemia, ckd, proteinuria, prior_left_chest_or_mediastinal_rt, current_or_significant_smoker, obesity. Age exclusive (>=75 High; 65-74 Medium 1; <65 none). LVEF exclusive (<50 High; 50-54 Medium 2; >=55 none). QTc exclusive (>=480 High; else sex-specific Medium 2). cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"high_factor": false,
"lvef_percent": 60,
"medium_points": 0,
"qtc_ms": 400,
"risk_level": "low",
"sex": "female",
"very_high_factor": false
},
{
"age_years": 50,
"cardiotoxicity_guide": "<2%",
"citation": {
"authors": "Lyon AR, Dent S, Stanway S, et al.",
"doi": "10.1002/ejhf.1920",
"id": "lyon-2020",
"pmid": "32458582",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
},
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false,
"tier": "very_high"
},
{
"factor": "arterial_vascular_disease",
"points": 0,
"present": false,
"tier": "very_high"
},
{
"factor": "venous_thrombosis",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "lvef_lt_50",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "qtc_ge_480",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "age_ge_75",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "hypertension",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "prior_anthracycline",
"points": 0,
"present": false,
"tier": "high"
},
{
"factor": "lvef_50_to_54",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "borderline_qtc",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "arrhythmia",
"points": 0,
"present": false,
"tier": "medium_2"
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "age_65_to_74",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "diabetes",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "hyperlipidemia",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "ckd",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "proteinuria",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false,
"tier": "medium_1"
},
{
"factor": "obesity",
"points": 0,
"present": false,
"tier": "medium_1"
}
],
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"formula": "hfa_icos_vegf",
"formula_expression": "HFA-ICOS VEGF-inhibitor class (Lyon 2020): very_high if any very-high factor; else high if any high factor or medium_points>=5; else medium if medium_points 2-4; else low. medium_points = Medium 2 + Medium 1 only. Very high: heart_failure_or_cardiomyopathy, arterial_vascular_disease (IHD, PCI, CABG, stable angina, TIA, stroke, or PVD). High: venous_thrombosis, lvef_percent<50, qtc_ms>=480, age_years>=75, hypertension, prior_anthracycline. Medium 2: lvef 50-54, male 450<=qtc<480, female 460<=qtc<480, arrhythmia (AF/flutter/VT/VF). Medium 1: elevated_troponin, elevated_bnp, age 65-74, diabetes, hyperlipidemia, ckd, proteinuria, prior_left_chest_or_mediastinal_rt, current_or_significant_smoker, obesity. Age exclusive (>=75 High; 65-74 Medium 1; <65 none). LVEF exclusive (<50 High; 50-54 Medium 2; >=55 none). QTc exclusive (>=480 High; else sex-specific Medium 2). cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"high_factor": false,
"lvef_percent": 60,
"medium_points": 0,
"qtc_ms": 400,
"risk_level": "low",
"sex": "female",
"very_high_factor": false
}
],
"path": "/api/calc/hfa_icos_vegf"
}Use with an agent
- Discover. Agents find this listing with
GET https://bazaar.saylorinnovations.com/discovery/search?query=…, the MCP toolsearch_resources, or/discovery/resources. - Inspect. Fetch
/resources/39589.jsonfor the price and payment options. - Pay. Call
GET https://api.magentlab.com/api/calc/hfa_icos_vegf. The provider answers402with its payment requirements. An x402 client signs one of the options below and retries withPAYMENT-SIGNATURE. - Execute. The provider returns
200with the data. Agent Bazaar is not in the request path and never sees your payment.
For humans
You don't need an account or an API key; you need a wallet holding a small amount of USDC on Base, and an x402-capable client (see the examples below). Call the endpoint unpaid first to see exactly what it asks for.
Pricing & payment
- Price
- $0.005 / request
- Protocol
- x402 v2
- Auth
- No account or API key. Pay per request.
- Networks
- Base
- Demand
- 3 calls · 1 unique payers in 30d (public x402 Bazaar data)
x402 payment requirements
| Scheme | Network | Asset | Amount | Pay to | Timeout |
|---|---|---|---|---|---|
| exact | Base eip155:8453 | USDC | $0.005 | 0x836Be278f1739fB4308091cD1852F7971Bc19Ee2 | 600s |
accepts[] (raw JSON)
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "5000",
"amountUsd": 0.005,
"maxTimeoutSeconds": 600
}
]Schemas
Output schema (JSON Schema)
{
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}Example shape — generated from the schema, not a captured live response
{
"example": {},
"type": "string"
}Examples
curl "https://api.magentlab.com/api/calc/hfa_icos_vegf"
# -> 402 Payment Required, accepts[] lists how to pay
# retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paidconst res = await fetch("https://api.magentlab.com/api/calc/hfa_icos_vegf");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}import httpx
res = httpx.get("https://api.magentlab.com/api/calc/hfa_icos_vegf")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerDetails
- Provider
- api.magentlab.com
- Endpoint
- https://api.magentlab.com/api/calc/hfa_icos_vegf
- Machine-readable
/resources/39589.json